Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apellis Pharmaceuticals, Inc. (APLS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer listed on the Nasdaq Global Select Market, Apellis uses filings such as Forms 10-K, 10-Q, 8-K, and others to report on its business, financial condition, risk factors, and material events related to its complement-based therapies SYFOVRE and EMPAVELI/Aspaveli.
In these filings, investors can review detailed information on revenue from SYFOVRE and EMPAVELI, research and development spending for ophthalmology and rare disease programs, and the status of key clinical trials such as GALE and VALIANT. Risk factor and management discussion sections typically describe the scientific and regulatory considerations associated with targeting C3 in geographic atrophy, C3 glomerulopathy, primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria.
Current reports on Form 8-K, such as the Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi), document material definitive agreements that affect Apellis’ economics, including ex-U.S. royalty structures for Aspaveli and related financing consents. These filings help clarify how collaborations and capital arrangements support the company’s commercialization and pipeline strategy.
On Stock Titan, Apellis filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly understand topics like royalty arrangements, cash runway, product revenue trends, and major clinical or regulatory milestones. Users can also review Forms 4 and other insider transaction reports to monitor trading activity by Apellis directors and executives, alongside proxy and governance disclosures that describe compensation and board oversight. This page is a central resource for analyzing the regulatory record behind APLS stock.
Apellis Pharmaceuticals insider activity: VP and Chief Accounting Officer James George Chopas reported a sale of Apellis Pharmaceuticals common stock mainly for tax purposes. On January 22, 2026, he sold 2,064 shares of common stock at a price of $21.7654 per share. According to the footnote, these shares were sold to cover tax withholding on Restricted Stock Units that were released on January 21, 2026. After this transaction, he continued to beneficially own 49,805 shares of Apellis common stock directly.
Apellis Pharmaceuticals reported an insider stock transaction by Chief Business & Strategy Officer Mark DeLong. On January 22, 2026, he sold 3,371 shares of Apellis common stock at $21.7654 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to restricted stock units that were released on January 21, 2026, meaning the sale was tied to equity compensation rather than an open-market liquidation of a larger position. After this sale, DeLong beneficially owned 78,353 shares of Apellis common stock.
Apellis Pharmaceuticals Chief Scientific Officer Pascal Deschatelets reported a sale of Apellis common stock in a Form 4 filing. On January 22, 2026, he sold 5,928 shares of common stock at a price of $21.7654 per share. According to the filing, these shares were sold to cover tax withholding obligations on restricted stock units that were released on January 21, 2026. After this transaction, Deschatelets directly beneficially owned 1,151,382 shares of Apellis common stock.
Apellis Pharmaceuticals, Inc. insider activity: Chief Executive Officer and director Cedric Francois reported selling 27,192 shares of Apellis common stock on January 22, 2026 at a price of
In addition to his direct holdings, the filing lists indirect holdings in several trusts, including 307,946 shares held by The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares held by The Cedric Francois Irrevocable Trust of 2023, 300,000 shares held by The Francois Grossi Trust, and 234,411 shares held by The Francois-DuBois Educational Trust. These shares are held by the respective trusts, and Francois disclaims beneficial ownership except to the extent of any pecuniary interest.
Apellis Pharmaceuticals chief technical officer files insider share sale
Apellis Pharmaceuticals chief technical officer Nur Nicholson reported selling 7,725 shares of Apellis common stock on January 22, 2026 at a price of $21.7654 per share. According to the filing, these shares were sold to cover tax withholding obligations arising from Restricted Stock Units that were released on January 21, 2026. After this transaction, Nicholson beneficially owned 71,118 shares of Apellis common stock held directly.
Apellis Pharmaceuticals, Inc. Chief Financial Officer Timothy Eugene Sullivan reported a sale of 10,287 shares of common stock on January 22, 2026. The shares were sold at a price of $21.7654 per share and the filing explains that this sale was made to cover tax withholding on Restricted Stock Units that were released on January 21, 2026.
After this tax‑related sale, Sullivan directly beneficially owned 93,901 shares of Apellis common stock. In addition, 60,396 shares are held indirectly through The Timothy E Sullivan Irrevocable Trust of 2023. The filing notes that the securities in the trust are held by that trust with Patrick O. Collins as trustee, and Sullivan disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest in them.
Apellis Pharmaceuticals General Counsel David O. Watson reported a sale of company common stock in an insider filing. On January 22, 2026, he sold 7,832 shares of Apellis common stock at $21.7654 per share, and the filing explains this sale was made to cover tax withholding on Restricted Stock Units that were released on January 21, 2026. After this transaction, he directly holds 88,531 common shares.
The filing also lists indirect holdings. A custodial account held by him for the sole benefit of his minor children holds 10,000 common shares50,136 common shares are held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The Watson Education Trust is shown with 0 shares, and he likewise disclaims beneficial ownership in that trust except for any pecuniary interest.
An individual holder of APLS common stock has filed a Rule 144 notice to sell 7,832 shares. The planned sale is to be executed through Fidelity Brokerage Services LLC on or about 01/22/2026 on the NASDAQ, with an indicated aggregate market value of $170,466.61. The filing notes that 126,525,218 shares of this class were outstanding.
The shares to be sold were acquired on 01/21/2026 via restricted stock vesting from the issuer as compensation, in the same amount of 7,832 shares. The notice also lists prior sales of APLS common stock by David O. Watson over the past three months, including transactions on 11/17/2025, 12/16/2025, 01/13/2026, and 01/20/2026 with gross proceeds ranging from about $48,987.43 to $128,242.01. The signer represents that they do not know of any undisclosed material adverse information about the issuer.
A shareholder of the company with symbol APLS has filed a notice of proposed sale of 5,928 shares of common stock under Rule 144. The shares, to be sold through Fidelity Brokerage Services LLC on the NASDAQ, have an aggregate market value of $129,025.30, while common shares outstanding are listed as 126,525,218. The shares were acquired on 01/21/2026 through restricted stock vesting from the issuer as compensation.
The filing also lists prior sales in the last three months by Pascal Deschatelets, who sold 2,277 common shares on 01/13/2026 for gross proceeds of $50,520.25 and 909 common shares on 01/20/2026 for $17,991.75. By signing the notice, the selling person represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
APLS insider Timothy E. Sullivan has filed a notice of proposed sale under Rule 144 for 10,287 shares of common stock, to be sold through Fidelity Brokerage Services on NASDAQ around 01/22/2026. The filing lists an aggregate market value of $223,900.67 for these shares and notes that 126,525,218 shares of the same class were outstanding at the time of the notice. The shares to be sold were acquired on 01/21/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Sullivan sold 3,856 shares for $85,553.84 on 01/13/2026 and 2,892 shares for $57,241.07 on 01/20/2026.